Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression - PubMed (original) (raw)
. 2009 Oct;17(10):1779-87.
doi: 10.1038/mt.2009.133. Epub 2009 Jun 16.
Vita S Salsman, Eric Yvon, Chrystal U Louis, Laszlo Perlaky, Winfried S Wels, Meghan K Dishop, Eugenie E Kleinerman, Martin Pule, Cliona M Rooney, Helen E Heslop, Stephen Gottschalk
Affiliations
- PMID: 19532139
- PMCID: PMC2835000
- DOI: 10.1038/mt.2009.133
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression
Nabil Ahmed et al. Mol Ther. 2009 Oct.
Abstract
Human epidermal growth factor receptor 2 (HER2) is expressed by the majority of human osteosarcomas and is a risk factor for poor outcome. Unlike breast cancer, osteosarcoma cells express HER2 at too low, a level for patients to benefit from HER2 monoclonal antibodies. We reasoned that this limitation might be overcome by genetically modifying T cells with HER2-specific chimeric antigen receptors (CARs), because even a low frequency of receptor engagement could be sufficient to induce effector cell killing of the tumor. HER2-specific T cells were generated by retroviral transduction with a HER2-specific CAR containing a CD28.zeta signaling domain. HER2-specific T cells recognized HER2-positive osteosarcoma cells as judged by their ability to proliferate, produce immunostimulatory T helper 1 cytokines, and kill HER2-positive osteosarcoma cell lines in vitro. The adoptive transfer of HER2-specific T cells caused regression of established osteosarcoma xenografts in locoregional as well as metastatic mouse models. In contrast, delivery of nontransduced (NT) T cells did not change the tumor growth pattern. Genetic modification of T cells with CARs specific for target antigens, expressed at too low a level to be effectively recognized by monoclonal antibodies, may allow immunotherapy to be more broadly applicable for human cancer therapy.
Figures
**Figure 1
Primary osteosarcomas and osteosarcoma cell lines express human epidermal growth factor receptor 2 (HER2) at low levels. (a) Using the HER2-specific mouse monoclonal antibody NCL-L-CB11 (Novocastra, Newcastle Upon Tyne, UK), seven of eight primary osteosarcoma samples representing different histological subtypes showed detectable HER2 expression. One of eight samples did not express HER2 (bottom right panel). (b) Fluorescence-activated cell sorter analysis: osteosarcoma cells lines (U2-OS, Sa-OS, HOS, SK-ES-1, MNNG, Hs 894, Hs 899, LM7, MG-63, SJSA-1, 143b, and 143.98.2) and breast cancer cell lines (HER2-negative: MDA-MB-468, HER2-low: MCF-7, HER2-high: SK-BR-3) were stained for HER2 expression (isotype control: open curves; HER2: solid curves. Osteosarcoma cell lines expressed HER2 at low levels comparable to MCF-7.
**Figure 2
Trastuzumab fails to inhibit the proliferation of human epidermal growth factor receptor 2 (HER2)-positive osteosarcoma cell lines. (a) Tumor cells were cultured for 4 days in the presence of increasing concentrations of trastuzumab prior to performing a proliferation assay. Trastuzumab efficiently inhibited the proliferation of the HER2-high expressing cell line SK-BR-3, where as no inhibition was observed for the HER2-low expressing cell lines Sa-OS, MG-63, HOS, MNNG, LM7 or the HER2-negative cell line MDA-MB-468. Results from two experiments; done in triplicates are shown. (b) To test for complement mediated cytotoxicity, 51Cr-labeled tumor cells incubated for 30–60 minutes with baby-rabbit complement in the presence of increasing concentrations of trastuzumab. While trastuzumab efficiently lysed the HER2-high expressing cell line SK-BR-3, no lysis was observed for the HER2-low expressing cell lines Sa-OS, U2-OS, MG-63, HOS, MNNG, LM7, or the HER2-negative cell line MDA-MB-468. Results from two experiments done in triplicates are shown.
**Figure 3
Characterization of human epidermal growth factor receptor 2 (HER2) CAR.CD28.ζ T cells. (a) Scheme of SFG retroviral vector encoding HER2.CD28.ζ CAR. (b) Depending on the donor, a median of 72% (range 45–92%) of T cells transduced with the HER2.CD28.ζ CAR retrovirus were positive for the transgene as judged by fluorescence-activated cell sorter analysis. CAR, chimeric antigen receptor.
**Figure 4
Human epidermal growth factor receptor 2 (HER2)-specific T cells secrete immunostimulatory cytokines, proliferate and kill HER2-expressing osteosarcoma cells in coculture. HER2-specific T cells were stimulated with HER2-positive (U2-OS, Sa-OS, SK-ES-1, MNNG, MG-63, HOS, Hs 894, Hs 899, and LM7) or HER2-negative (MDA-MB-468) cells. 24–48-hours poststimulation the (a) IFN-γ and (b) IL-2 concentration was determined. (c) T-cell proliferation was determined by counting viable cells (Trypan blue exclusion) 3 days poststimulation. Only HER2-specific T cells produced IFN-γ and IL-2 and proliferated after exposure to HER2-positive cells in comparison to nontransduced T cells. Results from three experiments from two donors done in duplicates are shown. (d) Only HER2-specific T cells killed HER2 positive osteosarcoma cells, in a 4 hour 51Cr-release cytotoxicity assay; nontransduced (NT) T cells did not. The HER2 negative cell line MDA-MB-468, and HER2-negative fibroblasts, lymphoblastoid B-cell lines (LCL) and T-cell blasts were not killed by HER2-specific or NT T cells. SK-BR-3 was used as a positive control. Results from three experiments done in triplicates are shown.
**Figure 5
Adoptively transferred human epidermal growth factor receptor 2 (HER2)-specific T cells induce regression of intraperitoneal osteosarcoma xenograft_s_. 2 × 106 LM7.eGFP.FFLuc cells were injected intraperitoneally in 9- to 12-week-old nonobese diabetic–severe combined immunodeficient mice (day 0) followed by intraperitoneal injection of 10 × 106 HER2-specific T cells or nontransduced T cells (NT T cells) on days 2, 3 and 4 or days 8, 9 and 10 after tumor inoculation. (a) Although tumors regressed over a period of 24–72 hours in response to injection of HER2-specific T cells (two lower rows), tumors grew progressively in untreated mice as shown for four representative animals and in mice receiving nontransduced T cells (upper two rows). (b) Quantitative bioluminescence imaging: the pretreatment bioluminescence values on day 2 were comparable between animals treated with HER2-specific T cells and those treated with NT T cells (P = 0.94). As early as 24 hours after initiation of treatment, the median photon emission from animals receiving HER2-specific T cells was significantly lower than those receiving NT T cells and for untreated tumors (P < 0.002 and _P_ < 0.008 for animals treated on day 2 and those treated on day 8, respectively). Values are corrected to background bioluminescence. Two-tailed _P_ value, Mann–Whitney U test are reported. Solid arrows: time of T-cell injection. (**c**) Survival analysis was performed at day 160. Mice from the untreated and NT T-cell control groups had a median survival of 63 days (range 29–66 days) and 65 days (range 49–104 days), respectively. Injection of HER2-specific T cells into mice bearing small or large tumors resulted in a significant survival advantage; mice bearing small tumors had a median survival of greater 160 days (_P_ < 0.001) where as mice bearing large tumors had a median survival of 88 days (range 62 to >160 days; P < 0.01).
**Figure 6
Adoptive transfer of human epidermal growth factor receptor 2 (HER2)-specific T cells induces regression of established osteosarcoma lung metastasis. 2 × 106 LM7.eGFP.FFLuc cells were injected systemically into the tail vein in 9- to 12-week-old Nu/Nu mice (day 0) followed by tail-vein injection of 10 × 106 HER2-specific T cells on days 2, 3, and 4 after tumor inoculation. (a) While tumors regressed in response to injection of HER2-specific T cells, tumors grew progressively in untreated mice. (b) Kaplan–Meier survival curve: mice treated with HER2-specific T cells had a significantly longer survival probability (P < 0.001) in comparison to untreated mice.
Similar articles
- Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells.
Mata M, Vera JF, Gerken C, Rooney CM, Miller T, Pfent C, Wang LL, Wilson-Robles HM, Gottschalk S. Mata M, et al. J Immunother. 2014 Oct;37(8):407-15. doi: 10.1097/CJI.0000000000000052. J Immunother. 2014. PMID: 25198528 Free PMC article. - T cells redirected to EphA2 for the immunotherapy of glioblastoma.
Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, Rainusso N, Wu MF, Liu H, Kew Y, Grossman RG, Powell S, Lee D, Ahmed N, Gottschalk S. Chow KK, et al. Mol Ther. 2013 Mar;21(3):629-37. doi: 10.1038/mt.2012.210. Epub 2012 Oct 16. Mol Ther. 2013. PMID: 23070117 Free PMC article. - Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
Sun M, Shi H, Liu C, Liu J, Liu X, Sun Y. Sun M, et al. Breast Cancer Res. 2014 Jun 11;16(3):R61. doi: 10.1186/bcr3674. Breast Cancer Res. 2014. PMID: 24919843 Free PMC article. - Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress.
Budi HS, Ahmad FN, Achmad H, Ansari MJ, Mikhailova MV, Suksatan W, Chupradit S, Shomali N, Marofi F. Budi HS, et al. Stem Cell Res Ther. 2022 Jan 29;13(1):40. doi: 10.1186/s13287-022-02719-0. Stem Cell Res Ther. 2022. PMID: 35093187 Free PMC article. Review. - Potential of human γδ T cells for immunotherapy of osteosarcoma.
Li Z. Li Z. Mol Biol Rep. 2013 Jan;40(1):427-37. doi: 10.1007/s11033-012-2077-y. Epub 2012 Oct 14. Mol Biol Rep. 2013. PMID: 23065272 Review.
Cited by
- The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence.
Barzegari A, Salemi F, Kamyab A, Aratikatla A, Nejati N, Valizade M, Eltouny E, Ebrahimi A. Barzegari A, et al. J Bone Oncol. 2024 Sep 22;48:100635. doi: 10.1016/j.jbo.2024.100635. eCollection 2024 Oct. J Bone Oncol. 2024. PMID: 39381633 Free PMC article. Review. - Near-infrared photoimmunotherapy for osteosarcoma targeting epidermal growth factor receptor.
Suzuki M, Kobayashi H, Hanaoka H. Suzuki M, et al. Transl Oncol. 2024 Dec;50:102132. doi: 10.1016/j.tranon.2024.102132. Epub 2024 Oct 1. Transl Oncol. 2024. PMID: 39357464 Free PMC article. - Advances on immunotherapy for osteosarcoma.
Yu S, Yao X. Yu S, et al. Mol Cancer. 2024 Sep 9;23(1):192. doi: 10.1186/s12943-024-02105-9. Mol Cancer. 2024. PMID: 39245737 Free PMC article. Review. - Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial.
Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, Gad AZ, Janeway KA, Campbell M, Mullikin D, Nawas Z, Robertson C, Mathew PR, Zhang H, Mehta B, Bhat RR, Major A, Shree A, Gerken C, Kalra M, Chakraborty R, Thakkar SG, Dakhova O, Salsman VS, Grilley B, Lapteva N, Gee A, Dotti G, Bao R, Salem AH, Wang T, Brenner MK, Heslop HE, Wels WS, Hicks MJ, Gottschalk S, Ahmed N. Hegde M, et al. Nat Cancer. 2024 Jun;5(6):880-894. doi: 10.1038/s43018-024-00749-6. Epub 2024 Apr 24. Nat Cancer. 2024. PMID: 38658775 Clinical Trial. - Overall review of curative impact and barriers of CAR-T cells in osteosarcoma.
Li G, Wang H, Meftahpour V. Li G, et al. EXCLI J. 2024 Mar 6;23:364-383. doi: 10.17179/excli2023-6760. eCollection 2024. EXCLI J. 2024. PMID: 38655095 Free PMC article. Review.
References
- Gurney JG, Swensen AR., and , Bulterys M. Malignant Bone Tumors. SEER Pediatric Monograph 2005100–110.Ref Type: Data File
- Link M, Gebhardt MC., and , Meyers PA.Osteosarcoma Principles and Practice of Pediatric Oncology 2006Lippincott Williams and Wilkins; 1074–1115.In: Philip, AP and David, GP (eds)5th edn
- Bacci G, Briccoli A, Longhi A, Ferrari S, Mercuri M, Faggioli F, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol. 2005;44:748–755. - PubMed
- Flint AF, U'Ren L, Legare ME, Withrow SJ, Dernell W., and , Hanneman WH. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Vet Pathol. 2004;41:291–296. - PubMed
- Gilbertson RJ. ERBB2 in pediatric cancer: innocent until proven guilty. Oncologist. 2005;10:508–517. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous